secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001013762-23-002985
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports positive preclinical psilocybin data for MASLD; Phase 1 in early 2024
--------------------------------------------------------------------------------

- Low-dose psilocybin (0.05 mg/kg, daily oral) in HFHFD mice reduced liver steatosis, body weight (12% reduction), and fasting blood glucose (p<0.05).
- Mechanism involves 5-HT-2A receptor agonism, distinct from GLP-1 agents; restored plasma/liver triglyceride levels to normal-diet levels.
- Company to initiate single-ascending dose Phase 1 trial in obese MASLD patients in early 2024.
- Data to be presented at AASLD The Liver Meeting 2023 (Nov 10-14, 2023, Boston).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/0001013762-23-002985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000101376223002985/ea186600-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-002985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer